Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cepheid

This article was originally published in The Gray Sheet

Executive Summary

Initial public offering of 5 mil. shares at $6 each June 21 represents a reduction in the originally proposed price range of $10-12 per share (1"The Gray Sheet" May 1, p. 19). The Sunnyvale, California maker of microfluidic systems for detection and analysis of nucleic acids plans to use the proceeds from the $30 mil. offering for R&D, expansion of manufacturing and other general corporate purposes. Cepheid shares trade on the Nasdaq market under the symbol "CPHD." Underwriters UBS Warburg, Prudential Vector Healthcare and Invemed Associates hold an overallotment option for 750,000 additional shares
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT013556

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel